Abstract: The present application discloses a metering device, including a structure body of the metering device, a first metering chip and a metering master control chip. The first metering chip is configured for performing fundamental wave and full wave processing on electric energy data; the metering master control chip includes a master control chip core, a coprocessor and a storage unit, wherein the master control chip core and the coprocessor share the storage unit; and the coprocessor is configured for performing harmonic processing on the electric energy data based on the storage unit and based on a manner of instruction. By applying the solution of the present application, the electric energy data of the metering device can be processed quickly and efficiently, and a hardware cost is saved at the same time. The present application also provides an electric energy meter which has the corresponding technical effects.

Abstract: Involved is an isolated antigen binding protein, being capable of binding CCR8 derived from a primate animal. Further involved are a pharmaceutical composition comprising the antigen binding protein, and an application of the antigen binding protein and/or the pharmaceutical composition in the prevention and/or treatment of a tumor or a cancer.

Abstract: A terminal functional side chain-substituted diketopyrrolopyrrole (DPP)-based terpolymer and a preparation method and use thereof is described herein. The terpolymer has the following structural formula: where R1 is a terminal siloxy-substituted swallow-tailed chain with 22 to 52 carbon atoms in total, and t1 and t2 each are an integer of 1 to 18; R2 is a semifluoroalkyl-substituted swallow-tailed chain with 12 to 60 carbon atoms in total and 10 to 46 fluorine atoms in total, t3 and t4 each are an integer of 1 to 16, and t5 and t6 each are an integer of 1 to 10; and Ar is any one selected from the group consisting of aryl, heteroaryl, substituent-containing aryl, and substituent-containing heteroaryl, and m and n each are an integer of 5 to 100.

Abstract: The invention relates to the field of Wushu facilities and provides a novel active wooden dummy comprising a lower limb assembly, an upper body assembly and two arm assemblies. The lower limb assembly is provided with a driving device and a vertical spindle. The spindle is vertically arranged. The upper body assembly is rotatably arranged on the spindle. The driving device drives the upper body assembly to repeatedly swing leftwards or rightwards. Each arm assembly comprises a front arm rod, a rear arm rod, a turning rod and a connection rod. Kinetic energy generated when the upper body assembly swings is used to drive the arm assemblies to stretch or retreat, the whole wooden dummy can be driven by one driving device to move, and the arm assemblies stretch or retreat when the upper body assembly swings, so as to simulate attack motions from opponents in actual combat.

Abstract: The invention relates to the field of Wushu facilities and provides a novel active wooden dummy comprising a lower limb assembly, an upper body assembly and two arm assemblies. The lower limb assembly is provided with a driving device and a vertical spindle. The spindle is vertically arranged. The upper body assembly is rotatably arranged on the spindle. The driving device drives the upper body assembly to repeatedly swing leftwards or rightwards. Each arm assembly comprises a front arm rod, a rear arm rod, a turning rod and a connection rod. Kinetic energy generated when the upper body assembly swings is used to drive the arm assemblies to stretch or retreat, the whole wooden dummy can be driven by one driving device to move, and the arm assemblies stretch or retreat when the upper body assembly swings, so as to simulate attack motions from opponents in actual combat.

Abstract: The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).

Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).

Abstract: Provided herein are a novel class of compounds of Formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.

Abstract: The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).

Abstract: The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).

Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).

Abstract: The invention provides novel pyrimidine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).

Abstract: The invention provides novel pyrimidine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK).

Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).

Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by G protein-coupled receptors, in particular G protein-coupled receptor 120.

Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).

Abstract: Provided herein are a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.

Abstract: The invention provides compounds having Formula Ia, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and Y are as defined in the specification; as well as pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).

Abstract: In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of the often chronic, severe and debilitating pain that can accompany inflammatory diseases and neuropathic insults, pain that is often unresponsive to conventional analgesic treatment. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of neuropathic pain, migraine-related pain and inflammatory pain with reduced sedative and ataxic side effects.